Silvia A Mandel

Author PubWeight™ 12.44^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.	Sci Transl Med	2010	3.48
2	A molecular signature in blood identifies early Parkinson's disease.	Mol Neurodegener	2012	1.13
3	Green tea polyphenol (-) -epigallocatechin-3-gallate promotes the rapid protein kinase C- and proteasome-mediated degradation of Bad: implications for neuroprotection.	J Neurochem	2006	0.89
4	A sporadic Parkinson disease model via silencing of the ubiquitin-proteasome/E3 ligase component SKP1A.	J Biol Chem	2009	0.86
5	DJ-1 deficiency triggers microglia sensitivity to dopamine toward a pro-inflammatory phenotype that is attenuated by rasagiline.	J Neurochem	2014	0.82
6	From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.	J Alzheimers Dis	2012	0.80
7	Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases.	Neurotherapeutics	2009	0.80
8	The novel multifunctional, iron-chelating drugs M30 and HLA20 protect pancreatic beta-cell lines from oxidative stress damage.	J Pharmacol Exp Ther	2010	0.79
9	Effects of novel neuroprotective and neurorestorative multifunctional drugs on iron chelation and glucose metabolism.	J Neural Transm (Vienna)	2012	0.78
10	Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism.	Neurodegener Dis	2010	0.78
11	Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.	Int Rev Neurobiol	2011	0.77
12	Silencing/overexpressing selected genes as a model of sporadic Parkinson's disease.	Neurodegener Dis	2010	0.76